Prophylactic administration of overproducing-abscisic acid Bacillus licheniformis attenuated DSS-induced colitis in mice by regulating the gut microbiota and immune activity. Xu, Zeyan (Z);Zhao, Lijiang (L);Wu, Mengting (M);Cui, Anqi (A);Chen, Wei (W);Zheng, Guohao (G);Zhou, Jingyi (J);Gao, Daqing (D);Shi, Ruihua (R); |
Author information BMC Microbiol.2025 May 19;25(1):306.doi:10.1186/s12866-025-03988-4 Abstract BACKGROUND: Inflammatory bowel disease (IBD) involves the complex interplay among the mucosal barrier, microbiota, immunity and genetic factors. There are currently no satisfactory treatments for IBD. Administration of the probiotic Bacillus licheniformis (Bl) can improves colitis by regulating the gut microbiota. The phytohormone abscisic acid (ABA) treatment has favorable effects on immunity, as well as on inflammatory diseases like colitis. We hypothesized that the expression of an additional cyp gene by the Bl to increase its ABA production would enhance its effects. |
© Copyright 2013-2025 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only.
Use of this website is governed by the GIHF terms of use and privacy statement.